Fig. 2.
Fig. 2. CD22 and BCR coligation prolongs BCR-mediated ERK-2 activation. (A) ERK-2 kinase assays were performed on lysates obtained after stimulating primary human tonsil B cells (2 × 107/lane) with media, immobilized CD22 MoAb HB22.7 (20 μg/mL), F(ab′)2 fragments of goat antihuman IgM (20 μg/mL), both, or CD40 (2 μg/mL). Immune complex kinase assays were performed using MBP as a substrate. (B) ERK-2 kinase assays of lysates obtained from Ramos cells (107/lane) stimulated as described in (A).

CD22 and BCR coligation prolongs BCR-mediated ERK-2 activation. (A) ERK-2 kinase assays were performed on lysates obtained after stimulating primary human tonsil B cells (2 × 107/lane) with media, immobilized CD22 MoAb HB22.7 (20 μg/mL), F(ab′)2 fragments of goat antihuman IgM (20 μg/mL), both, or CD40 (2 μg/mL). Immune complex kinase assays were performed using MBP as a substrate. (B) ERK-2 kinase assays of lysates obtained from Ramos cells (107/lane) stimulated as described in (A).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal